References
- Kim YD. Heart Failure with Preserved Ejection Fraction: Current Diagnostic and Therapeutic Approach. 2016;90(1):20-25.
- Park JJ, Choi DJ. Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. Korean J Med. 2015;88(2):127-134. https://doi.org/10.3904/kjm.2015.88.2.127
- Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262-70. https://doi.org/10.1067/mhl.2002.124554
- Na SJ, Bae SH. Optimal Management of Heart Failure with Preserve Ejection Fraction. Korean J Med. 2015;88(2):135-141. https://doi.org/10.3904/kjm.2015.88.2.135
- Lee JH, Koo BK. Pleural Effusion in Cardiovascular Disease. Korean J Med. 2011;81(2):161-166.
- Jeong MJ, Kang KW, Kang JY et al. An Overview of the Applicability of Oryung-san as an Antihypertensive Agent. J. Int. Korean Med. 2017;38(4):443-454. https://doi.org/10.22246/jikm.2017.38.4.443
- 조기호, 권승원. 경계 너머의 한방처방. 경기:물고기숲. 2012:201.
- 張仲景. 元.鄧珍本金匱要略2-4b~2-5a. 燎原書店復刻版. 1988. 86-87.
- EZAKI H, INOKUCHI T, TANIWAKI M, YAMAMOTO H, DOI H, MIYAKE T, SAKURADA M. Efficacy of Mokuboito in Patients with Severe Intractable Heart Failure. Kampo Medicine. 2016;67(2):169-177. https://doi.org/10.3937/kampomed.67.169
- Otsuka,K. Kampo-lgaku(漢方医学), Osaka:Sougen-sha. 1973:150.
- 조한진, 이경섭. 목방기탕(木防己湯)이 강심이뇨 및 심장박동에 미치는 영향. 대한한의학회지. 1984;5(1): 28-34.
- Seiichiro Nishida, Hiroyasu Satoh. Vascular Pharmacology of Mokuboito (Mu-Fang-YiTang) and Its Constituents on the Smooth Muscle and the Endothelium in Rat Aorta. eCAM. 2007;4(3):335-341.
- Nishida S, Satoh H. Vascular pharmacology of mokuboito(mu-fang-yi-tang) and its constituents on the smooth muscle and the endothelium in rat aorta. Evid Based Complement Alternat Med. 2007;4:335-341. https://doi.org/10.1093/ecam/nel097
- Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol. 1998;30:451-463. https://doi.org/10.1016/S0306-3623(97)00309-1
- 한의과대학 방제학교수 공편저. 방제학. 서울:영림사; 2003:504-6.
- Ito Y. Pathophysiology of the Goreisan show lowering of osmolality set point. Japanese Journal of Oriental Medicine. 1978;28:91-9.
- Isohama Y. Modulation of aquaporin water channel function by Kampo medicines. Kampo and the newest therapy. 2008;17:27-35.
- Kurita T, Nakamura K, Tabuchi M, Orita M, Ooshima K, Higashino H. Effects of Goreisan: a traditional Japanese Kampo medicine, on aquaporin 1, 2, 3, 4 and V2R mRNA expression in rat kidney and forebrain. J Med Sci. 2011;11(1):30-8. https://doi.org/10.3923/jms.2011.30.38
- Kim SY. Influence of Goryeosin infusion solution on the change of serum electrolytes in rats. Dajeon Univ 1990:1-38.
- Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417. https://doi.org/10.1016/j.jjcc.2019.05.003
- Shuji YAKUBO, Yuko KINOSHITA, Yasuyuki ARAKAWA, Masanao TAKA-HAsHI, Susumu KITANAKA. Clinical evaluation of Moku-boi-to(Mu-Fang-Yi-Tang):A Japanese and Chinese traditional medicine for heart failure. J.Trad.Med. 2002;19:159-163.
- Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417. https://doi.org/10.1016/j.jjcc.2019.05.003
- Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012;42:153-163. https://doi.org/10.1111/j.1365-2362.2011.02573.x